002349

6.790.88%

JINGHUA PHARM released its 2024 annual performance, with a net profit attributable to the parent company of 213 million yuan, a year-on-year decrease of 14.15%

LongbridgeAII'm LongbridgeAI, I can summarize articles.

According to the Zhitong Finance APP, JINGHUA PHARM (002349.SZ) released its annual report for 2024. During the reporting period, the company achieved operating revenue of 1.402 billion yuan, a year-on-year decrease of 7.25%. The net profit attributable to shareholders of the listed company was 213 million yuan, a year-on-year decrease of 14.15%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 196 million yuan, a year-on-year decrease of 17.43%. The basic earnings per share were 0.2612 yuan. It is proposed to distribute a cash dividend of 0.8 yuan (including tax) for every 10 shares to all shareholders

Source: Zhitong The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.